A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy
Sponsor: Eli Lilly and Company • ClinicalTrials.gov ID: NCT07654972
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
The main purpose of this study is to understand how safe and well-tolerated LY4174794 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4174794 gets into the bloodstream and how long it takes the body to eliminate it. Participation in this study will last about 30 to 39 weeks (7 to 10 months).
Interventions
-
LY4174794
(Drug)
Administered SC.
-
LY4174794
(Drug)
Administered IV.
-
Placebo
(Drug)
Administered SC.
Eligibility criteria
Conditions
Locations
- ICON Early Phase Services, LLC — San Antonio, Texas, United States
- ICON Early Phase Services, LLC — Salt Lake City, Utah, United States
- Lilly Centre for Clinical Pharmacology — Singapore, Singapore
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record